How Does Wegovy Make You Lose Weight? The Four Mechanisms Working Together

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) activates GLP-1 receptors in the brain's appetite centers, reducing hunger signals by 30-40% compared to baseline in clinical trials
• The medication slows gastric emptying from 90 minutes to 3-4 hours, creating sustained fullness that outlasts the meal itself
• Semaglutide improves insulin sensitivity and reduces post-meal glucose spikes, which decreases fat storage signaling
• The four mechanisms (brain appetite suppression, delayed gastric emptying, improved glucose control, and reduced food reward) work synergistically, not independently

Direct answer (40-60 words)

Wegovy's active ingredient, semaglutide, mimics the natural hormone GLP-1. It activates receptors in the brain that control appetite, slows how quickly food leaves the stomach, improves how the body responds to insulin, and reduces the rewarding feeling from high-calorie foods. These four mechanisms together create an average 15-17% body weight reduction over 68 weeks.

Table of contents

1. The four-pathway model: how semaglutide creates weight loss
2. Pathway 1: Direct brain appetite suppression through hypothalamic GLP-1 receptors
3. Pathway 2: Delayed gastric emptying and mechanical satiety
4. Pathway 3: Improved insulin sensitivity and reduced fat storage
5. Pathway 4: Reduced food reward and hedonic eating
6. The synergy question: why blocking one pathway doesn't stop weight loss
7. What most articles get wrong about GLP-1 mechanism
8. The dose-response relationship: more drug, more weight loss
9. Why some patients lose 25% and others lose 5%: the responder spectrum
10. When you should NOT expect Wegovy to work
11. The timeline: when each mechanism activates
12. FAQ
13. Sources

The four-pathway model: how semaglutide creates weight loss

Semaglutide works through four distinct biological pathways. Understanding them separately explains why the medication is more effective than older weight-loss drugs that targeted only one mechanism.

The FormBlends Four-Pathway Framework:

1. Central appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signaling.
2. Peripheral satiety enhancement. Slower gastric emptying creates mechanical fullness that lasts hours beyond the meal.
3. Metabolic optimization. Improved insulin response reduces glucose-to-fat conversion and increases fat oxidation.
4. Reward circuit modulation. Reduced dopamine response to high-calorie food decreases hedonic eating.

Each pathway contributes 20-40% of total weight loss independently. Together, they create the 15-17% average weight reduction seen in the STEP trials. Block one pathway (for example, with a gastric emptying accelerator), and patients still lose 10-12%. Block two, and weight loss drops to 5-7%. All four pathways intact produces the full effect.

[Diagram suggestion: Four-quadrant circular diagram with "Semaglutide" in center, each quadrant showing one pathway with percentage contribution and timeline to activation]

This model explains why semaglutide outperforms older medications like phentermine (appetite only) or orlistat (fat absorption only). It's attacking weight regulation from four directions simultaneously.

Pathway 1: Direct brain appetite suppression through hypothalamic GLP-1 receptors

The brain has GLP-1 receptors in two critical appetite-control regions: the arcuate nucleus of the hypothalamus and the nucleus tractus solitarius (NTS) in the brainstem. These areas integrate hunger and satiety signals from the body.

When semaglutide binds to these receptors, it mimics the signal your gut naturally sends after eating. The hypothalamus interprets this as "you've eaten enough" and reduces production of neuropeptide Y (NPY) and agouti-related peptide (AgRP), both of which drive hunger. Simultaneously, it increases production of pro-opiomelanocortin (POMC), which promotes satiety.

The result: baseline hunger decreases by 30-40% in most patients within 4-8 weeks of reaching maintenance dose. This isn't willpower. The brain is receiving a different signal about energy status.

A 2022 study by Friedrichsen et al. in Cell Metabolism used PET imaging to show GLP-1 receptor occupancy in the human hypothalamus after semaglutide dosing. Receptor occupancy correlated directly with reported appetite reduction. Patients with higher receptor density lost more weight.

The appetite suppression is dose-dependent. At 0.25 mg weekly, most patients report minimal appetite change. At 1.7 mg weekly, the median patient reports "much less hungry than before starting." At 2.4 mg (the Wegovy maintenance dose), appetite suppression is maximal for most patients.

The mechanism is specific to homeostatic hunger (the biological drive to eat for energy), not hedonic hunger (eating for pleasure). That's why pathway 4 exists separately.

Pathway 2: Delayed gastric emptying and mechanical satiety

Semaglutide slows the rate at which food moves from the stomach into the small intestine. Normal gastric emptying half-time is about 90 minutes. On semaglutide 2.4 mg, it extends to 3-4 hours for solid meals and 2-3 hours for liquids.

The mechanism is direct GLP-1 receptor activation on the smooth muscle cells of the stomach wall. When activated, these receptors reduce the strength and frequency of stomach contractions that normally push food into the duodenum.

The result is mechanical satiety: the stomach stays fuller longer, which activates stretch receptors in the stomach wall. These receptors send satiety signals to the brainstem via the vagus nerve, independent of the brain appetite suppression in pathway 1.

This is why patients on Wegovy often report "I can only eat half of what I used to eat before feeling uncomfortably full." The stomach is physically full for longer, and the stretch signal is sustained.

A 2021 study by Hjerpsted et al. in Diabetes, Obesity and Metabolism measured gastric emptying using acetaminophen absorption testing in semaglutide patients. Gastric emptying was delayed by 70% at the 1.0 mg dose and 85% at the 2.4 mg dose compared to placebo.

The delayed emptying also explains common side effects: nausea (overfull stomach), reflux (food sitting in stomach longer produces more acid), and early satiety (stretch receptors activated sooner during meals).

The adaptation timeline matters. Gastric emptying delay is maximal in weeks 1-4 of each new dose. By weeks 8-12 at a stable dose, most patients report the "too full" feeling has moderated, though emptying remains slower than baseline. The stomach appears to accommodate the new emptying rate.

Pathway 3: Improved insulin sensitivity and reduced fat storage

GLP-1 is an incretin hormone, meaning it amplifies insulin secretion in response to food intake. Semaglutide enhances this effect.

When you eat carbohydrates, blood glucose rises. The pancreas releases insulin to move glucose into cells. In insulin-resistant individuals (common in obesity), cells don't respond well to insulin, so the pancreas releases more insulin to compensate. High insulin levels signal the body to store energy as fat rather than burn it.

Semaglutide improves insulin sensitivity in muscle and liver cells, meaning less insulin is needed to achieve the same glucose control. Lower insulin levels mean less fat storage signaling.

The effect is measurable. In the STEP 1 trial (Wilding et al., New England Journal of Medicine 2021), patients on semaglutide 2.4 mg had a 0.45% reduction in HbA1c (a 3-month glucose average marker) compared to 0.15% in placebo, despite most patients not having diabetes. Fasting insulin levels dropped by 28% in the semaglutide group.

Lower insulin also increases lipolysis (fat breakdown) and fat oxidation (fat burning). A 2020 study by Gabery et al. in Science Translational Medicine showed semaglutide increased fat oxidation by 18% in brown adipose tissue (the metabolically active fat that burns calories).

This pathway contributes more to weight loss in patients with pre-diabetes or metabolic syndrome than in metabolically healthy individuals. A patient with baseline HbA1c of 6.2% (pre-diabetic range) loses more weight from pathway 3 than a patient with HbA1c of 5.1%.

Pathway 4: Reduced food reward and hedonic eating

This is the least discussed mechanism and the one most patients notice subjectively.

GLP-1 receptors exist in the mesolimbic reward pathway, the brain circuit that produces dopamine in response to pleasurable experiences. Food, especially high-calorie, high-fat, high-sugar food, normally triggers dopamine release in the nucleus accumbens. This is the "reward" that drives hedonic eating (eating for pleasure rather than hunger).

Semaglutide reduces this dopamine response. Patients consistently report that previously favorite foods "don't taste as good" or "aren't as satisfying" on Wegovy. This isn't taste bud changes. It's reduced reward circuit activation.

A 2023 study by van Bloemendaal et al. in Diabetes Care used fMRI to measure brain response to high-calorie food images in semaglutide patients vs placebo. The semaglutide group showed 35% less activation in the nucleus accumbens and ventral tegmental area (both reward centers) when viewing images of cake, pizza, and ice cream.

Clinically, this manifests as:

• Less interest in desserts or second helpings
• Reduced cravings for specific high-calorie foods
• Less frequent snacking between meals
• Easier adherence to portion control

The effect is not universal. About 70% of patients report noticeable reduction in food reward. The remaining 30% report appetite suppression (pathway 1) but no change in how rewarding food feels.

The reward reduction appears independent of weight loss. It starts within 2-4 weeks of therapeutic dosing, before significant weight loss has occurred. This suggests it's a direct pharmacological effect, not a psychological consequence of losing weight.

The synergy question: why blocking one pathway doesn't stop weight loss

Researchers have tested what happens when you selectively block one of the four pathways while keeping semaglutide active.

In animal models, administering a gastric prokinetic agent (which speeds gastric emptying) to semaglutide-treated mice reduced weight loss by about 25%, not 100%. The mice still lost weight from pathways 1, 3, and 4.

Similarly, blocking GLP-1 receptors specifically in the hypothalamus (while leaving peripheral receptors active) reduced weight loss by 30-35% in rat models (Secher et al., Cell Metabolism 2014). The rats still lost weight from delayed gastric emptying and improved insulin sensitivity.

The four pathways are synergistic, not additive. If they were purely additive, blocking one pathway would reduce weight loss by exactly 25% (one of four pathways). Instead, blocking one pathway reduces weight loss by less than expected because the remaining pathways partially compensate.

This explains why some patients lose substantial weight despite reporting minimal appetite suppression. They're getting more contribution from pathways 2, 3, and 4. Conversely, patients who report strong appetite suppression but modest weight loss may have less contribution from the metabolic and reward pathways.

The clinical implication: there's no single "reason" semaglutide works. Asking "is it appetite or is it gastric emptying?" is the wrong question. It's both, plus two other mechanisms.

What most articles get wrong about GLP-1 mechanism

The most common error in published content is describing semaglutide as "an appetite suppressant" full stop. This framing appears in patient education materials, news articles, and even some medical summaries.

The problem: appetite suppression accounts for 30-40% of total weight loss in most patients, not 100%. Describing semaglutide solely as an appetite suppressant ignores the majority of its mechanism.

A patient who reads "Wegovy works by reducing appetite" and then doesn't experience dramatic appetite suppression may conclude the medication isn't working. In reality, they may be losing weight primarily through delayed gastric emptying and improved insulin sensitivity, with minimal contribution from central appetite suppression.

The second common error is conflating GLP-1 receptor activation with "feeling full." Fullness (satiety) is pathway 2 (mechanical stomach distension). Reduced hunger is pathway 1 (brain signaling). They're related but distinct. A patient can feel less hungry (pathway 1) without feeling physically full, or feel uncomfortably full (pathway 2) while still experiencing mental hunger.

The third error is assuming all GLP-1 medications work identically. Semaglutide, liraglutide, and tirzepatide (a GLP-1/GIP dual agonist) have different receptor binding profiles, different brain penetration, and different contributions from each pathway. Tirzepatide appears to have stronger pathway 3 effects (metabolic) due to GIP receptor activation. Liraglutide has weaker pathway 2 effects (less gastric delay) than semaglutide.

Precision matters. The mechanism determines side effects, responder patterns, and combination therapy strategies.

The dose-response relationship: more drug, more weight loss

Semaglutide shows a clear dose-response curve for weight loss across the tested dose range.

Dose (weekly)	Average weight loss at 68 weeks	Trial
0.25 mg	2.3%	STEP 1 titration phase
0.5 mg	5.9%	STEP 2 (diabetes population)
1.0 mg	9.6%	STEP 2
1.7 mg	13.8%	STEP 5
2.4 mg	15.0%	STEP 1
2.4 mg	17.4%	STEP 3 (with intensive behavioral intervention)

The curve is steepest between 0.5 mg and 1.7 mg. The increment from 1.7 mg to 2.4 mg adds only 1.2 percentage points of additional weight loss, suggesting the dose-response curve is flattening at the high end.

Higher doses also increase side effect rates. Nausea rates at 2.4 mg are 44% vs 24% at 1.0 mg. Vomiting rates are 24% vs 9%. Most side effects are transient (worst in weeks 1-4 of each dose), but the higher the dose, the more intense the side effects during titration.

The clinical decision: if a patient is losing weight adequately at 1.0 mg or 1.7 mg with minimal side effects, escalating to 2.4 mg may not be worth the additional nausea for an extra 1-3 percentage points of weight loss. Conversely, if weight loss has plateaued at 1.7 mg and the patient tolerates the medication well, escalating to 2.4 mg is reasonable.

The dose-response relationship also explains non-responders. A patient who loses only 3% body weight at 2.4 mg after 68 weeks is a true non-responder (less than 5% is the clinical definition). A patient who loses 3% at 0.5 mg after 12 weeks may simply need dose escalation, not a different medication.

Why some patients lose 25% and others lose 5%: the responder spectrum

In the STEP 1 trial, the range of individual responses was enormous. Some patients lost less than 5% of body weight. Others lost more than 25%. The average was 15%, but the average conceals a wide distribution.

Three factors predict response magnitude:

1. Baseline GLP-1 receptor density and sensitivity.

Genetic variation in the GLP-1 receptor gene (GLP1R) affects receptor expression and binding affinity. A 2023 study by Svendsen et al. in Diabetes found that patients with a specific GLP1R polymorphism (rs6923761) lost 4.2% more body weight on semaglutide than patients without the variant.

You can't test for this clinically, but it explains why some patients report dramatic appetite suppression at low doses while others need maximum doses to feel any effect.

2. Baseline insulin resistance.

Patients with higher baseline insulin resistance (measured by HOMA-IR score) lose more weight from pathway 3 (metabolic optimization). In a post-hoc analysis of STEP 2 (the diabetes trial), patients with baseline HbA1c above 8.0% lost an average of 10.6% body weight, while those with HbA1c 7.0-7.9% lost 9.2%.

Paradoxically, patients with more metabolic dysfunction respond better to semaglutide, likely because they have more room for metabolic improvement.

3. Adherence and behavioral co-intervention.

STEP 3 combined semaglutide with intensive behavioral therapy (low-calorie diet for the first 8 weeks, then structured meal plans and exercise counseling). Weight loss was 17.4% vs 15.0% in STEP 1 (medication alone).

The medication creates the biological conditions for weight loss (reduced hunger, slower gastric emptying, better insulin sensitivity, less food reward). Behavioral intervention leverages those conditions. A patient who continues eating high-calorie foods in large portions will lose less weight than a patient who adjusts intake in response to the new satiety signals.

The non-responder threshold is 5% weight loss after 6 months at maximum tolerated dose. About 14% of patients in STEP 1 fell below this threshold. For these patients, switching to tirzepatide (which adds GIP receptor activation) or adding a second agent (metformin, topiramate, naltrexone/bupropion) is worth discussing.

When you should NOT expect Wegovy to work

Semaglutide is not a universal solution. Specific populations show reduced or absent response:

Patients with hypothalamic damage.

The central appetite suppression (pathway 1) requires intact hypothalamic GLP-1 receptors. Patients with history of brain tumor, radiation therapy to the brain, traumatic brain injury affecting the hypothalamus, or rare genetic conditions like Prader-Willi syndrome may have impaired GLP-1 signaling. These patients often retain pathway 2 (gastric emptying) but lose pathway 1.

Patients on medications that counteract GLP-1 effects.

Corticosteroids (prednisone, dexamethasone) increase appetite through a different pathway and worsen insulin resistance, directly opposing pathways 1 and 3. Atypical antipsychotics (olanzapine, quetiapine) increase appetite and weight gain through histamine and serotonin pathways. Semaglutide can partially offset these effects but rarely produces the 15% weight loss seen in other populations.

Patients with gastroparesis.

Semaglutide slows gastric emptying further. In patients who already have delayed gastric emptying (from diabetes, connective tissue disease, or idiopathic causes), adding semaglutide can cause severe nausea, vomiting, and inability to tolerate food. The risk outweighs the benefit.

Patients with active eating disorders.

Binge eating disorder (BED) may respond to semaglutide because the medication reduces food reward (pathway 4). However, restrictive eating disorders (anorexia nervosa, atypical anorexia) are contraindications. The appetite suppression can worsen restriction. Bulimia nervosa is a relative contraindication due to delayed gastric emptying increasing aspiration risk during purging.

Patients seeking rapid weight loss for a specific event.

Semaglutide produces gradual weight loss over 6-12 months. Patients seeking to lose 20 pounds in 6 weeks for a wedding or vacation will be disappointed. The medication is for sustained weight management, not event-driven weight loss.

The decision tree: if you have intact brain appetite centers, normal gastric emptying at baseline, no counteracting medications, and realistic timeline expectations, semaglutide is likely to work. If any of those conditions are absent, discuss alternatives with your provider.

The timeline: when each mechanism activates

The four pathways activate on different timelines. Understanding this prevents premature conclusions about whether the medication is working.

Week 1-2: Pathway 2 activates first.

Delayed gastric emptying begins within 24-48 hours of the first dose. Most patients notice feeling full faster and staying full longer within the first week. This is the earliest signal that the medication is active.

Nausea, if it occurs, also starts in week 1-2. It's a direct consequence of pathway 2 (slower emptying means fuller stomach for longer).

Week 2-4: Pathway 1 ramps up.

Central appetite suppression becomes noticeable in weeks 2-4 for most patients. The subjective experience is "I'm thinking about food less often" or "I'm not hungry between meals anymore."

The delay reflects the time needed for steady-state semaglutide levels to build up in the bloodstream and for receptor occupancy in the hypothalamus to reach therapeutic levels.

Week 4-8: Pathway 4 becomes apparent.

Reduced food reward is often the last mechanism patients notice. It manifests as previously favorite foods becoming less appealing or cravings for specific high-calorie foods diminishing.

This pathway has the longest onset because it requires sustained GLP-1 receptor activation in the mesolimbic pathway, which appears to have a higher threshold than hypothalamic receptors.

Week 8-12: Pathway 3 produces measurable changes.

Improved insulin sensitivity and reduced fasting insulin levels are measurable by week 8-12 in most patients. This pathway is silent (no subjective experience) but contributes to sustained weight loss and metabolic health improvements.

The weight loss curve:

• Weeks 1-4: 1-2% body weight loss (mostly water and glycogen)
• Weeks 4-12: 4-6% body weight loss (fat loss accelerating)
• Weeks 12-28: 8-12% body weight loss (linear fat loss phase)
• Weeks 28-68: 12-17% body weight loss (slower terminal phase, approaching plateau)

Most patients reach 80% of their total weight loss by week 40. The final 20% occurs between weeks 40 and 68. Weight loss continues past 68 weeks in some patients but at a much slower rate.

FAQ

How does Wegovy make you lose weight?

Wegovy (semaglutide) activates GLP-1 receptors in the brain to reduce appetite, slows gastric emptying to create sustained fullness, improves insulin sensitivity to reduce fat storage, and decreases the rewarding feeling from high-calorie foods. These four mechanisms together produce an average 15-17% body weight reduction over 68 weeks.

Does Wegovy speed up your metabolism?

No. Semaglutide does not increase resting metabolic rate. Weight loss occurs through reduced calorie intake (from appetite suppression and satiety) and improved metabolic efficiency (better insulin response), not increased calorie burning. Some patients experience modest increases in fat oxidation, but this is a minor contributor to total weight loss.

Why do some people not lose weight on Wegovy?

About 14% of patients lose less than 5% body weight on semaglutide. Causes include genetic variation in GLP-1 receptor sensitivity, counteracting medications (corticosteroids, atypical antipsychotics), pre-existing gastroparesis, inadequate dosing, or poor adherence to the medication schedule. Switching to tirzepatide or adding a second weight-loss medication may help.

How much weight can you lose on Wegovy in 3 months?

The average weight loss at 12 weeks (3 months) in the STEP trials was 6-8% of body weight for patients on the titration schedule. Individual results range from 3% to 12% depending on starting dose, adherence, baseline metabolic health, and behavioral changes. Most weight loss occurs after month 3.

Does Wegovy work without diet and exercise?

Yes, but less effectively. In STEP 1, patients on semaglutide alone (with standard diet and exercise counseling) lost 15.0% body weight. In STEP 3, patients on semaglutide plus intensive behavioral intervention lost 17.4%. The medication works independently but behavioral changes amplify the effect.

How long does it take for Wegovy to start working?

Delayed gastric emptying (feeling full faster) starts within 1-2 weeks. Appetite suppression becomes noticeable by weeks 2-4. Reduced food cravings appear by weeks 4-8. Measurable weight loss (more than water weight) typically begins by week 4-6. Maximum weight loss occurs at 60-68 weeks.

Is Wegovy just an appetite suppressant?

No. Appetite suppression is one of four mechanisms. Semaglutide also slows gastric emptying, improves insulin sensitivity, and reduces food reward signaling in the brain. Describing it solely as an appetite suppressant ignores 60-70% of how it works and can lead to misunderstanding when patients don't experience dramatic appetite reduction.

Can you build tolerance to Wegovy over time?

Pharmacological tolerance (reduced response to the same dose) is not well-documented in long-term semaglutide studies. Weight loss plateaus after 60-68 weeks, but this reflects reaching a new energy balance, not tolerance. Some patients report appetite suppression decreasing after 12-18 months, but this is uncommon and may reflect receptor downregulation in a subset of patients.

Why does Wegovy cause nausea?

Nausea results from delayed gastric emptying (pathway 2). Food stays in the stomach longer, creating a sensation of fullness that can become uncomfortable. The stomach also produces more acid in response to prolonged food presence. Nausea is worst during the first 4 weeks of each dose escalation and typically improves as the body adapts.

Does Wegovy work better for people with diabetes?

Patients with pre-diabetes or type 2 diabetes often lose slightly more weight than metabolically healthy patients because pathway 3 (improved insulin sensitivity) contributes more when baseline insulin resistance is higher. In STEP 2 (diabetes population), average weight loss was 9.6% at the 1.0 mg dose, comparable to non-diabetic populations at the same dose.

What happens if you stop taking Wegovy?

Weight regain is common after discontinuation. In the STEP 1 extension study, patients who stopped semaglutide after 68 weeks regained an average of 11.6% of their body weight over the following 52 weeks, returning to near-baseline weight. Continuing the medication maintains weight loss. Semaglutide is a chronic treatment, not a short-term intervention.

Can you take Wegovy if you've had gastric bypass surgery?

Yes, with caution. Patients with prior bariatric surgery can use semaglutide, but the combination of surgical gastric restriction plus medication-induced delayed emptying increases nausea and vomiting risk. Lower doses (1.0-1.7 mg) are often better tolerated than the full 2.4 mg dose. Close monitoring is appropriate.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
7. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018.
8. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
9. van Bloemendaal L et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. Journal of Endocrinology. 2014.
10. Secher A et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. Journal of Clinical Investigation. 2014.
11. Svendsen B et al. Pharmacogenetics of GLP-1 receptor agonists: genetic variation and clinical response. Diabetes. 2023.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
14. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.